CXCR4 and diffuse large B-cell lymphoma: In the current study, CXCR4 expression was associated with poorer OS (P= .0016) and PFS (P= .0017) in a large cohort of 468 de novo DLBCL patients treated with R-CHOP (Figures 1H-I) and poorer therapy response in 236 GCB-DLBCLs.